Women With GDM Have Elevated Risk of Future Cardiac Events

Share this content:
Women With GDM Have Elevated Risk of Future Cardiac Events
Women With GDM Have Elevated Risk of Future Cardiac Events

FRIDAY, Nov. 11, 2016 (HealthDay News) -- The risk of cardiovascular outcomes is elevated for women with gestational diabetes mellitus (GDM), even in the absence of subsequent type 2 diabetes mellitus (T2DM), according to a study published online Nov. 7 in Diabetes Care.

Ravi Retnakaran, M.D., from Mount Sinai University in Toronto, and Baiju R. Shah, M.D., Ph.D., from the University of Toronto, examined the role of T2DM in determining vascular outcomes in women with previous GDM. Women with a live-birth pregnancy between April 1994 and March 2014 were stratified into four groups: women with GDM in whom T2DM developed (15,585 women); women with GDM in whom T2DM did not develop (41,299 women); women without GDM in whom T2DM developed (49,397 women); and women with neither GDM nor T2DM (1,408,798 women). Participants were followed for a median of 10.0 years.

The researchers found that among women with GDM, those in whom T2DM developed had elevated risks of vitrectomy/photocoagulation, renal dialysis, and hospitalization for foot infection (hazard ratios, 4.49, 7.52, and 4.32, respectively; all P < 0.0001). Although absolute event rates were very low, the risks of cardiovascular disease and coronary artery disease were increased for both women with GDM in whom T2DM developed and in those in whom T2DM did not develop.

"Future macrovascular risk is an inherent feature of GDM, irrespective of subsequent T2DM," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »